Sure no worries
- Manufacture of MPL tablets. The covid excuse is rubbish.
- Lack of follow up from the original ONJ Research. Was it 2015 the original work was done?
- Covid work on MPL. All over the place at best
- CEO of an Australian based Biotech who lives in London. You think this would have assisted with the covid work in the Netherlands recently (it didn't). I cant see in anyway that it has been a benefit to us as shareholders having our CEO based in London
- Phase 2 trial that attracted 6 dogs. There were probably bigger at forces at play when Elanco chose not to take up the option. However being presented with a study on 6 dogs didn't demonstrate to the "vet major" that they were missing out on anything that they would later come to regret.
As I've said before, I've got the feeling they are waiting for the royalty period on MPL to expire. Might be a good time to change leadership to really kick this strategy/any strategy into gear.
Sure no worriesManufacture of MPL tablets. The covid excuse is...
-
- There are more pages in this discussion • 47 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $89.08M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 175242 | 23.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.0¢ | 10000 | 1 |
View Market Depth
| Last trade - 16.13pm 19/06/2024 (20 minute delay) ? |
| PAA (ASX) Chart |
Day chart unavailable